Thromb Haemost 1990; 64(03): 358-360
DOI: 10.1055/s-0038-1647318
Original Article
Schattauer GmbH Stuttgart

Subcutaneous Desmopressin (DDAVP) Shortens the Prolonged Bleeding Time in Patients with Liver Cirrhosis

Marco Cattaneo
The “A. Bianchi Bonomi” Hemophilia and Thrombosis Center and Institute of Internal Medicine, Maggiore Hospital and University of Milan, Italy
,
Paola M Tenconi
The “A. Bianchi Bonomi” Hemophilia and Thrombosis Center and Institute of Internal Medicine, Maggiore Hospital and University of Milan, Italy
,
Ignazio Alberca
*  Department of Hematology, University of Salamanca, Spain
,
Vicente Vicente Garcia
*  Department of Hematology, University of Salamanca, Spain
,
Pier Mannuccio Mannucci
The “A. Bianchi Bonomi” Hemophilia and Thrombosis Center and Institute of Internal Medicine, Maggiore Hospital and University of Milan, Italy
› Author Affiliations
Further Information

Publication History

Received 22 February 1990

Accepted after revision08 June 1990

Publication Date:
25 July 2018 (online)

Summary

The intravenous infusion of 1-deamino-8-D-arginine vasopressin (DDAVP) shortens the prolonged bleeding time in patients with congenital or acquired bleeding disorders, including patients with uremia or liver cirrhosis. We carried out a double-blind, placebo-controlled crossover study in ten patients with liver cirrhosis to evaluate whether or not their prolonged bleeding times could be shortened by subcutaneous injections of DDAVP (0.3 μg/kg), a more practical route of administration than intravenous infusions. One hour after DDAVP injection the bleeding time was significantly shortened (p <0.05). After 4 h, however, the bleeding time shortening was no longer statistically significant. There was no bleeding time change after placebo. Plasma levels of von Willebrand factor antigen (vWF: Ag) did not significantly increase after DDAVP or placebo. The study shows that subcutaneous DDAVP is an alternative method for shortterm shortening of the bleeding time in liver cirrhosis.